| Schedule of reconciliation of net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
July 30, |
|
July 31, |
|
July 30, |
|
July 31, |
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to shareholders |
|
$ |
(12,691) |
|
$ |
(4,249) |
|
$ |
(24,587) |
|
$ |
(7,476) |
Earnings allocated to participating share awards |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Net loss attributable to common shares — Basic and diluted |
|
$ |
(12,691) |
|
$ |
(4,249) |
|
$ |
(24,587) |
|
$ |
(7,476) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding — Basic (a) (b) |
|
|
26,662,037 |
|
|
19,101,652 |
|
|
24,181,920 |
|
|
17,314,317 |
Dilutive effect of stock options, non-vested shares and warrants |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Weighted average number of common shares outstanding — Diluted |
|
|
26,662,037 |
|
|
19,101,652 |
|
|
24,181,920 |
|
|
17,314,317 |
Net loss per common share |
|
$ |
(0.48) |
|
$ |
(0.23) |
|
$ |
(1.02) |
|
$ |
(0.45) |
Net loss per common share — assuming dilution |
|
$ |
(0.48) |
|
$ |
(0.23) |
|
$ |
(1.02) |
|
$ |
(0.45) |
|
(a) |
For the three and six-month periods ended July 30, 2022, the basic earnings per share computation included 3,763,022 outstanding fully paid warrants to purchase shares of the Company’s common stock at a price of $0.001 per share. For the three and six-month periods ended July 31, 2021 the basic earnings per share computation included 21,000 outstanding fully paid warrants to purchase shares of the Company’s common stock at a price of $0.001 per share.
|
|
(b) |
Common warrants which are considered participating securities of 7,263,884 have been excluded because the Company had a net loss for the three and six-month periods ended July 30, 2022.
|
|